中华内分泌外科杂志
中華內分泌外科雜誌
중화내분비외과잡지
CHINESE JOURNAL OF ENDOCRINE SURGERY
2013年
6期
463-465
,共3页
贝前列素钠%糖尿病肾病%血管内皮生长因子%内皮素%尿微量白蛋白排泄率
貝前列素鈉%糖尿病腎病%血管內皮生長因子%內皮素%尿微量白蛋白排洩率
패전렬소납%당뇨병신병%혈관내피생장인자%내피소%뇨미량백단백배설솔
Beraprost sodium%Diabetic nephropathy%Vascular endothelial growth factor%Endothelin%UAER
目的 观察贝前列素钠对老年2型糖尿病肾病(diabetic nephropathy,DN)患者的临床疗效,并观察患者血浆血管内皮生长因子(vascular endothelial growth factor,VEGF)及内皮素-1(endothelin-1,ET-1)水平的变化.方法 将48例老年2型糖尿病肾病患者按随机数字分类法分为常规治疗组和贝前列素钠治疗组2组,另外27例2型老年糖尿病无肾病患者为对照组,测定各组治疗前后VEGF及ET-1水平的变化,探讨血浆VEGF及ET-1水平变化在糖尿病肾病发病中的可能作用.结果 2型糖尿病肾病患者较2型糖尿病无肾病患者血浆VEGF及ET-1水平明显升高[VEGF为(4.68 ±0.97) pg/L,ET-1为(138±9) ng/L] (P ＜0.01),差异有统计学意义,与常规治疗组比较应用贝前列素钠可使糖尿病肾病患者血浆VEGF及ET-1水平明显降低[VEGF为(2.82 ±0.14) pg/L,ET-1为(72±4)ng/L](均P＜0.05),差异有统计学意义,尿白蛋白排泄率(urinary albumin excretion rates,UAER)明显降低[UAER(89±27) mg/24 h](P＜0.05),差异有统计学意义.结论 VEGF及ET-1水平升高在糖尿病肾病的发病中发挥重要作用.贝前列素钠治疗可纠正糖尿病肾病患者血浆VEGF和ET-1平衡失调,改善糖尿病肾病内皮功能,降低尿蛋白,对糖尿病肾病有保护作用.
目的 觀察貝前列素鈉對老年2型糖尿病腎病(diabetic nephropathy,DN)患者的臨床療效,併觀察患者血漿血管內皮生長因子(vascular endothelial growth factor,VEGF)及內皮素-1(endothelin-1,ET-1)水平的變化.方法 將48例老年2型糖尿病腎病患者按隨機數字分類法分為常規治療組和貝前列素鈉治療組2組,另外27例2型老年糖尿病無腎病患者為對照組,測定各組治療前後VEGF及ET-1水平的變化,探討血漿VEGF及ET-1水平變化在糖尿病腎病髮病中的可能作用.結果 2型糖尿病腎病患者較2型糖尿病無腎病患者血漿VEGF及ET-1水平明顯升高[VEGF為(4.68 ±0.97) pg/L,ET-1為(138±9) ng/L] (P ＜0.01),差異有統計學意義,與常規治療組比較應用貝前列素鈉可使糖尿病腎病患者血漿VEGF及ET-1水平明顯降低[VEGF為(2.82 ±0.14) pg/L,ET-1為(72±4)ng/L](均P＜0.05),差異有統計學意義,尿白蛋白排洩率(urinary albumin excretion rates,UAER)明顯降低[UAER(89±27) mg/24 h](P＜0.05),差異有統計學意義.結論 VEGF及ET-1水平升高在糖尿病腎病的髮病中髮揮重要作用.貝前列素鈉治療可糾正糖尿病腎病患者血漿VEGF和ET-1平衡失調,改善糖尿病腎病內皮功能,降低尿蛋白,對糖尿病腎病有保護作用.
목적 관찰패전렬소납대노년2형당뇨병신병(diabetic nephropathy,DN)환자적림상료효,병관찰환자혈장혈관내피생장인자(vascular endothelial growth factor,VEGF)급내피소-1(endothelin-1,ET-1)수평적변화.방법 장48례노년2형당뇨병신병환자안수궤수자분류법분위상규치료조화패전렬소납치료조2조,령외27례2형노년당뇨병무신병환자위대조조,측정각조치료전후VEGF급ET-1수평적변화,탐토혈장VEGF급ET-1수평변화재당뇨병신병발병중적가능작용.결과 2형당뇨병신병환자교2형당뇨병무신병환자혈장VEGF급ET-1수평명현승고[VEGF위(4.68 ±0.97) pg/L,ET-1위(138±9) ng/L] (P ＜0.01),차이유통계학의의,여상규치료조비교응용패전렬소납가사당뇨병신병환자혈장VEGF급ET-1수평명현강저[VEGF위(2.82 ±0.14) pg/L,ET-1위(72±4)ng/L](균P＜0.05),차이유통계학의의,뇨백단백배설솔(urinary albumin excretion rates,UAER)명현강저[UAER(89±27) mg/24 h](P＜0.05),차이유통계학의의.결론 VEGF급ET-1수평승고재당뇨병신병적발병중발휘중요작용.패전렬소납치료가규정당뇨병신병환자혈장VEGF화ET-1평형실조,개선당뇨병신병내피공능,강저뇨단백,대당뇨병신병유보호작용.
Objective To observe the effect of beraprost sodium on elderly patients with type 2 diabetic nephropathy (DN) and to observe the change of the plasma vascular endothelial growth factor(VEGF) and endothelin(ET-1) level.Methods The levels of plasma VEGF and ET-1 in the 27 cases of type 2 diabetes without nephropathy and 48 cases with type 2 diabetic nephropathy were measured.The possible role of VEGF and ET-1 in diabetic nephropathy was explored.48 cases of type 2 diabetic nephropathy patients were randomly divided into 2 groups:the conventional treatment group and beraprost sodium treatment group.The changes of VEGF and ET-1 level in the 2 groups before and after the treatment were measured.Results The plasma VEGF and ET-1 levels were significantly higher in type 2 diabetic nephropathy patients than in type 2 diabetes patients without nephropathy(P ＜0.01).Compared with the control group,beraprost sodium significantly reduced the plasma VEGF and ET-1 levels in patients with diabetic nephropathy(P ＜ 0.05),and also reduced urinary albumin excretion rates (UAER) significantly (P ＜ 0.05).Conclusions The increasing level of VEGF and ET-1 plays an important role in the onset of diabetic nephropathy.Beraprost sodium can correct the balance of the plasma VEGF and ET-1 in treatment of patients with diabetic nephropathy,improves the endothelial function in diabetic nephropathy,decreases urine protein,and plays a protective role in diabetic nephropathy.
